Anti-infectives Partnering and Deal-Making Conference 2016

Over the years, the anti-Infectives field has faced the same challenges in areas such as pricing and reimbursement and overcoming resistance in diseases. However, drug approvals over the past year and President Obama's recent proposal to spend $1.2 billion to address antimicrobial resistance are indications that the field is still changing and evolving.

Draft Sessions
I. Infectious Diseases Where are we and where are we going
II. Non- traditional approaches and technologies in Anti-Infectives
III. Partnering in Anti-Infectives: Best Practices and Lessons Learned.
IV. Recent Deals & Advances in Anti- Infectives
V. New Government Initiatives and Non-Dilutive Funding
VI. New Approaches to Regulations